Methamphetamine-triggered coronary slow flow: A case report

Year 2025, Volume: 42 Issue: 4, 482 - 484, 31.12.2025

Yusuf Hoşoğlu , Sezer Markirt , Erkan Markirt , Veysi Kavalcı

Abstract

Methamphetamine use is a growing public health concern with significant cardiovascular consequences, including coronary vasospasm, myocardial injury, and arrhythmias. We describe a 38-year-old man with a five-year history of weekly methamphetamine use who presented with chest pain, palpitations, and elevated troponin levels two hours after drug intake. Although his electrocardiogram was non-ischemic, coronary angiography demonstrated normal epicardial arteries with coronary slow flow, most pronounced in the left anterior descending artery. Despite the absence of obstructive disease, the clinical and laboratory findings were consistent with myocardial infarction with non-obstructive coronary arteries (MINOCA). The corrected TIMI frame count confirmed diffuse slow flow, and a toxicology screen was positive for methamphetamine. The patient was treated with diltiazem, aspirin, and statin therapy, and was discharged in stable condition after 72 hours. At three-month follow-up, he remained symptom-free and abstinent from methamphetamine. This case highlights the uncommon coexistence of MINOCA and coronary slow flow related to methamphetamine use, suggesting a central role of microvascular dysfunction and coronary vasoreactivity. Routine toxicology screening should be considered in young patients with atypical myocardial infarction presentations to better understand and manage substance-related coronary pathophysiology.

Keywords

Methamphetamine , coronary slow flow , MINOCA

Ethical Statement

Ethics Approval Statement As this study is a single-patient case report that does not involve experimental intervention or identifiable personal information beyond clinical relevance, ethics committee approval was not deemed necessary.

References

• Mantinieks D, Archer M, Schumann J, Drummer OH, Gerostamoulos D. Methylamphetamine toxicity and its involvement in death: A retrospective observational study of deaths reported to the Victorian Coroner, Australia. Forensic Sci Med Pathol. 2024;20:852–62.
• Reddy PKV, Ng TMH, Oh EE, Moady G, Elkayam U. Clinical characteristics and management of methamphetamine‐ associated cardiomyopathy: State‐of‐the‐art review. J Am Heart Assoc. 2020;9:e016704.
• Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, et al. Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019;39:1739–46.
• Lindahl B, Baron T, Albertucci M, Prati F. Myocardial infarction with non-obstructive coronary artery disease. EuroIntervention. 2021;17:e875–87.
• Gök M, Örnek E, Kurtul A. Reasonability of urine toxicology screening for methamphetamine and cocaine in young acute myocardial infarction. Turk J Clin Lab. 2020;11:72–6.
• Zheng XZ, Shi YY, Chen KQ, Qiao XL, Wang LY. Evaluation of regional myocardial perfusion in methamphetamine abusers using real-time myocardial contrast echocardiography. Med Ultrason. 2019;21:56–61.
• Zhu Q, Wang S, Huang X, Zhao C, Wang Y, Li X, et al. Understanding the pathogenesis of coronary slow flow: Recent advances. Trends Cardiovasc Med. 2024;34:137–44.
• Scalone G, Niccoli G, Crea F. Editor’s choice – Pathophysiology, diagnosis and management of MINOCA: an update. Eur Heart J Acute Cardiovasc Care. 2019;8:54–62.
• Aparicio A, Cuevas J, Morís C, Martin M. Slow coronary blood flow: Pathogenesis and clinical implications. Eur Cardiol. 2022;17:e08.